PerkinElmer appoints Payal Agrawaal as MD - India & South Asia
She will lead efforts to deepen regional market presence, foster innovation, and support scientific advancement across South Asia
She will lead efforts to deepen regional market presence, foster innovation, and support scientific advancement across South Asia
First and only TROP2-directed therapy approved in the US for the treatment of lung cancer
25 women students to receive internship, training, and mentorship in Life Sciences segment
Launches FSSAI’s inclusive campaign to stop obesity with multilingual, sign language outreach and multi-platform media engagement under Eat Right India programme
Vepdegestrant is the first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a Phase 3 clinical trial and the first to show benefit in patients with breast cancer
First pivotal Phase 3 trial to show superiority of Keytruda plus a TROP2 antibody-drug conjugate, Trodelvy, versus standard of care in first-line metastatic TNBC
Pivotal results from the Phase 3 Breakwater trial showed 51% risk reduction in death compared to standard-of-care treatment
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30%
IICP is a registered charitable society working in the disability sector since 1974
Subscribe To Our Newsletter & Stay Updated